OPKO Phase 3 hGH-CTP Adult Trial Results 2017

J.P. Morgan equity research alert on OPKO's phase 3 study of hGH-CTP in adults with growth hormone deficiency, which failed to meet its primary endpoint on trunk fat mass reduction. Despite the disappointing adult results, the company initiated its pediatric phase 3 study, which represents approximately 75% of the total market opportunity.